Turbo Mckwek schreef op 15 juli 2021 17:40:
Speciaal voor luchtschip hier ook een copy pastje.
Gewoon even om haar verhaal te ontkrachten dat vaccineren helemaal geen risico's met zich mee brengt.
Maar ja, daar mag je het niet over hebben, want dat is allemaal flauwekul.
Risico's wegen niet op tegen de baten enzo.
En dat laatste, ja, gedeeltelijk waar. Deze vlieger gaat zeker op voor de risico groep.
Maar mijn dochter van 6 en 12 laten vaccineren?
Nou, ik wil (vooralsnog) dat risico niet nemen.
Is dat nou zo onbegrijpelijk?
Nou doe ik even een stelling, volgens mij zijn er meer gezonde mensen overleden door de vaccinatie dan dat er gezonde kinderen aan corona zijn overleden.
(de cijfers heb ik niet paraat, dus ik kan er heel goed naast zitten. En als dat zo is, dan hoor ik het graag)
[i]For public awareness and in the interest of transparency, CDC is providing timely updates on the following serious adverse events of interest:
Anaphylaxis after COVID-19 vaccination is rare and has occurred in approximately 2 to 5 people per million vaccinated in the United States. Severe allergic reactions, including anaphylaxis, can occur after any vaccination. If this occurs, vaccination providers can effectively and immediately treat the reaction. Learn more about COVID-19 vaccines and allergic reactions, including anaphylaxis.
Thrombosis with thrombocytopenia syndrome (TTS) after Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19 vaccination is rare. As of July 12, 2021, more than 12.8 million doses of the J&J/Janssen COVID-19 Vaccine have been given in the United States. CDC and FDA identified 38 confirmed reports of people who got the J&J/Janssen COVID-19 Vaccine and later developed TTS. Women younger than 50 years old especially should be aware of the rare but increased risk of this adverse event. There are other COVID-19 vaccine options available for which this risk has not been seen. Learn more about J&J/Janssen COVID-19 Vaccine and TTS.
To date, two confirmed cases of TTS following mRNA COVID-19 vaccination (Moderna) have been reported to VAERS after more than 321 million doses of mRNA COVID-19 vaccines administered in the United States. Based on available data, there is not an increased risk for TTS after mRNA COVID-19 vaccination.
CDC and FDA are monitoring reports of Guillain-Barré Syndrome (GBS) in people who have received the J&J/Janssen COVID-19 Vaccine. GBS is a rare disorder where the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis. Most people fully recover from GBS, but some have permanent nerve damage. After 12.8 million J&J/Janssen COVID-19 Vaccine doses administered, there have been around 100 preliminary reports of GBS identified in VAERS. These cases have largely been reported about 2 weeks after vaccination and mostly in men, many 50 years and older. CDC will continue to monitor for and evaluate reports of GBS occurring after COVID-19 vaccination and will share more information as it becomes available.
Myocarditis and pericarditis after COVID-19 vaccination are rare. As of July 12, 2021, VAERS has received 1,047 reports of myocarditis or pericarditis among people ages 30 and younger who received a COVID-19 vaccine.
Reports of death after COVID-19 vaccination are rare. More than 334 million doses of COVID-19 vaccines were administered in the United States from December 14, 2020, through July 12, 2021. During this time, VAERS received 6,079 reports of death (0.0018%) among people who received a COVID-19 vaccine. FDA requires healthcare providers to report any death after COVID-19 vaccination to VAERS, even if it’s unclear whether the vaccine was the cause. Reports of adverse events to VAERS following vaccination, including deaths, do not necessarily mean that a vaccine caused a health problem.